Edwin Young
Internal Medicine · Auburn, MANPI 1437130366
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 455 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 455 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Boehringer Ingelheim$851
- Pfizer$716
- Lilly USA, LLC$572
- Johnson & Johnson$506
- Novo Nordisk$500
- plus $3K from 21 others
What the payments were for
- Food & beverage$7,968100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 92 | $1,731 |
| Boehringer Ingelheim | 43 | $851 |
| Pfizer | 41 | $716 |
| Lilly USA, LLC | 36 | $572 |
| Johnson & Johnson | 28 | $506 |
| Novo Nordisk | 31 | $500 |
| Amarin Pharma, Inc. | 22 | $405 |
| Merck | 23 | $353 |
| Teva Pharmaceuticals USA, Inc. | 24 | $343 |
| GSK | 19 | $315 |
| AbbVie(2 entities) | 15 | $261 |
| Amgen | 17 | $248 |
| Astellas Pharma US Inc | 9 | $186 |
| Sanofi-aventis U.S. LLC | 8 | $177 |
| E.r. Squibb & Sons, L.L.C. | 7 | $128 |
| Novartis | 6 | $127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $118 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $86 |
| Sunovion Pharmaceuticals Inc. | 5 | $83 |
| Vanda Pharmaceuticals Inc. | 2 | $58 |
| Jazz Pharmaceuticals Inc. | 4 | $56 |
| Endo Pharmaceuticals Inc. | 2 | $34 |
| Sanofi Pasteur Inc. | 2 | $29 |
| Almatica Pharma LLC | 1 | $28 |
| Mylan Specialty L.p. | 1 | $24 |
| Redhill Biopharma Inc. | 1 | $20 |
| Abbott | 1 | $18 |
How this compares
$7,974 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 19 | $469 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Auburn
- David SchenkeinBoston$5M
- Alan GarberCambridge$4.9M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Sandra RichmanBrookline$1.4M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.